- Home
- MIRA vs BCDA Comparison
MIRA vs BCDA Comparison
Compare MIRA & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- BCDA
- Stock Information
- Founded
- MIRA 2020
- BCDA N/A
- Country
- MIRA United States
- BCDA United States
- Employees
- MIRA N/A
- BCDA N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- BCDA Health Care
- Exchange
- MIRA Nasdaq
- BCDA Nasdaq
- Market Cap
- MIRA 17.1M
- BCDA 7.9M
- IPO Year
- MIRA 2023
- BCDA N/A
- Fundamental
- Price
- MIRA $1.05
- BCDA $2.60
- Analyst Decision
- MIRA Strong Buy
- BCDA Strong Buy
- Analyst Count
- MIRA 2
- BCDA 1
- Target Price
- MIRA $14.00
- BCDA $25.00
- AVG Volume (30 Days)
- MIRA 552.1K
- BCDA 74.1K
- Earning Date
- MIRA 11-11-2024
- BCDA 11-06-2024
- Dividend Yield
- MIRA N/A
- BCDA N/A
- EPS Growth
- MIRA N/A
- BCDA N/A
- EPS
- MIRA N/A
- BCDA N/A
- Revenue
- MIRA N/A
- BCDA $428,000.00
- Revenue This Year
- MIRA N/A
- BCDA $6.92
- Revenue Next Year
- MIRA N/A
- BCDA N/A
- P/E Ratio
- MIRA N/A
- BCDA N/A
- Revenue Growth
- MIRA N/A
- BCDA 0.71
- 52 Week Low
- MIRA $0.51
- BCDA $1.96
- 52 Week High
- MIRA $6.40
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- MIRA 38.97
- BCDA 46.60
- Support Level
- MIRA $1.04
- BCDA $2.39
- Resistance Level
- MIRA $1.20
- BCDA $2.84
- Average True Range (ATR)
- MIRA 0.07
- BCDA 0.17
- MACD
- MIRA 0.02
- BCDA -0.00
- Stochastic Oscillator
- MIRA 19.44
- BCDA 41.18
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).